The Fair Work Commission has found a former PricewaterhouseCoopers director should not have relied solely on a colleague’s text message in deciding to resign while on leave, rejecting her argument that the accounting firm had essentially forced her resignation.
A judge will not allow a law firm that stepped in to lead class actions against Hyundai and Kia to amend its funding proposal to seek a group costs order ahead of a carriage fight, even though its proposal would have led to greater returns for group members.
Mayfair 101’s James Mawhinney has defeated bankruptcy action by the owner of marketing firm 360 Degree Media, who claimed the founder of the beleaguered wealth management business owed him $3.5 million.
The Australian Council of Trade Unions is planning to challenge junior pay rates at the Fair Work Commission, arguing that the deck is unfairly stacked against young people.
Fortescue has brought legal action against start-up Element Zero and three former employees, alleging “industrial scale misuse” of the Western Australian mining company’s confidential information.
After an 18-month investigation, the Office of the Australian Information Commissioner has lodged civil penalty proceedings against Medibank over its October 2022 data breach, accusing the health insurer of breaching the Privacy Act.
The High Court has dismissed an appeal of a decision which found Indonesia’s national airline could avail itself of foreign state immunity to defeat a winding up application.
Unanimously dismissing an appeal by thoroughbred breeding and horseracing giant Godolphin, the High Court has ruled on the proper construction of a tax exemption for rural land in NSW.
The online safety watchdog has dropped her Federal Court action seeking to force X to put a worldwide block on graphic footage of the April stabbing of a religious leader at Wakeley, following a judge’s decision not to maintain an injunction against the social media platform.
Drug giant Pfizer has blasted Samsung Bioepis’ “fishing expedition” in its suit alleging infringement of the patent for its blockbuster arthritis drug Enbrel, telling the court the Korean biotech should not be allowed to dig for new grounds of invalidity.